The Senate Health, Education, Labor & Pensions Committee today held a hearing examining the administration’s blueprint to lower prescription drug prices. Health and Human Services Secretary Alex Azar testified on steps the agency is taking to implement the blueprint. For example, Azar noted, the Centers for Medicare & Medicaid Services recently unveiled updates to its drug-pricing dashboard and warned Medicare Part D plan sponsors that their contracts with pharmacies should not prevent the pharmacist from telling customers when they can get a better deal on a drug by paying cash; and the Food and Drug Administration also recently began publicly identifying drug companies suspected of blocking access to samples needed to test generic drugs. Among other actions, he said HHS is working to require drug companies to include their list price in their television commercials; give Medicare Part D plans market-based tools to negotiate better deals with drug companies; and “bring negotiation to Medicare Part B.”

Related News Articles

Headline
The AHA today voiced support for a Centers for Medicare…
Headline
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under…
Headline
The Campaign for Sustainable Rx Pricing, of which the AHA is a founding member, yesterday released a new ad urging Congress to keep its commitment to lower…
Headline
The Centers for Medicare…
Headline
The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling…
Headline
Seventeen organizations, including the AHA, today urged Congress to resist any attempts from the pharmaceutical industry to undo during the lame duck session…